Nov 04, 2014 (ACCESSWIRE via COMTEX) — TORONTO, ON / ACCESSWIRE / November 4, 2014 / Nevada-based Modern Mobility Aids, Inc. (OTC Pink: MDRM) (the “Company”), a medical device and Biopharma company, announces that it has created a Medical Advisory Board for the Company, and in an earlier press release announced that Dr. Baseer Khan, the Company’s Chief Medical Director, will serve as Chairman.
The Medical Advisory Board (Advisory Board) comprises primarily of doctors in various fields of medicine in which cannabis has been used either experimentally or in a medical prescription capacity. While each member of this board has established themselves as a leader within their respective fields, it was imperative to have representation from the full expanse of medical fields in which medical cannabis has indications.
The Advisory Board will serve to inform and advise management in biomedical research and the medical prescriptive use of cannabis in the bests interests of patient welfare. The Advisory Board will make recommendations to management that promotes education and awareness within the company and the medical community at large regarding the known effects of the use of cannabis. The Advisory Board will also do research on scientific programs of interest to management.
The Advisory Board may consist of up to 10 members whose terms may be up to 4 years and renewable. Appointments are made by the President of the company in consultation with the CMD. The CEO and President of the company are ex officio members of the Advisory Board.
Members of the Advisory Board are:
Baseer U. Khan, MD, FRCS(C)
Dr. Khan uniquely brings both medical and business expertise to MDRM. Clinically, Dr. Khan is an internationally recognized surgeon, researcher, and consultant. He is an Assistant Professor, University of Toronto and Executive Lead Physician, Eye Institute, Southlake Regional Hospital, Newmarket Ontario. Corporately, Dr. Khan founded and established the largest private ophthalmic practice in Toronto (Clarity Eye Institute), and is a managing partner and CIO of Oneview Procurement Solutions.
Gilbert Sharpe, Esq.
Gilbert Sharpe is a partner in the Health Law Group at the Toronto based law firm of Fasken Martineau. Mr. Sharpe, the former long-time Director of the Legal Branch of the Ontario Ministry of Health and Long-Term Care, brings invaluable experience from a distinguished 30-year career in legal practice and advisory roles. His background in public policy, private sector involvement and college regulatory work is a great asset to MDRM. Through his involvement with the Ministry of Health since 1975, and associated work with numerous ministries and agencies of the Ontario government as well as federal departments, Mr. Sharpe has been involved continuously with important legal issues and policy matters affecting health care, including the development of legislation and policies to improve the health care system. As well, he has been an advocate for educational forums to promote ongoing and effective exchange of information related to new initiatives. Since leaving the Ontario government, Mr. Sharpe has continued to work on numerous health law and policy matters for various clients, both in the private and public sectors. Mr. Sharpe holds several professorships (Professor, Faculty of Health Sciences, McMaster University; Professor, Faculty of Medicine, University of Toronto) as well as other positions including President of the Canadian Institute of Law and Medicine and Editor-in-Chief of Health Law in Canada. He is a member of the Canadian Bar Association and the Ontario Bar Association.
Dr. Peter J. Rothbart, MD, FRCP, DABPM:
Founder of the Rothbart Center for Pain Care and the Past President of the Chronic Pain Section of the Ontario Medical Association, Dr. Rothbart is recognized internationally as a leader and pioneer in the area of Chronic Pain Management.
Dr. Keith Jarvi, MD, FRCS
Dr. Jarvi is the Director of the Murray Koffler Urologic Wellness Centre and Head of Urology at the Mount Sinai Hospital. He is a Professor of Surgery at the University of Toronto and directs the Male Infertility Program at the University of Toronto. Dr. Jarvi has pioneered several echniques in urological surgery, published extensively on his research interests, and is internationally recognized in his field.
Dr. J. Brendan M. Mullen, MD, FRCP
Dr. Mullen is currently Director of the Andrology Laboratory and Deputy Director of Laboratories in the Department of Pathology and Laboratory Medicine at Mount Sinai Hospital and Laboratory Director for Flow Health Services Incorporated. He is an Associate Professor of Laboratory Medicine and Pathobiology, Anesthesia and Urology at the University of Toronto. He chaired and been consulted on a many provincial initiatives focused on identification and implementation of best practice policies. Dr. Mullen is heavily involved in research and has published extensively.
Dr. Paul Sanghera, MD, FRCS
Dr. Sanghera is on staff at Mount Sinai Hospital, in the department of Ophthalmology, and the Kensington Eye Institute, both located in Toronto, Ontario. He also serves as the co-chairman of the International Ophthalmology Program at the University of Toronto. A innovator and teacher, Dr. Sanghera was one of the first surgeons in Canada to perform laser cataract surgery, and in 2014, he co-created and co-chaired Canada’s first laser cataract teaching symposium.
Dr. Duncan A. Scott, MD, FRCPC
Dr. Scott’s principle focus is on forensic psychiatry however Dr. Scott has a wide ranging field of expertise and acts as an expert witness for both the Crown and defense attorneys. Among his many professional affiliations, he is a member of the Canadian Society of Medical Examiners, Canadian Academy of Psychiatry and Law and a past President of the Association of Physicians in Corrections of Ontario.
Dr. Adam Blackman, MD, D.ABSM, D.ABPN, FRCPC
Dr. Blackman is a board certified psychiatrist who sub-specialized in Sleep Medicine. He is the founder and Chief Medical Director of Medsleep, the past hair of the Section on Sleep Disorders of the Ontario Medical Association and an Assessor for the College of Physicians and Surgeons of Ontario. He has been a member of multiple committees responsible for the Clinical and Best Practice Guidelines. As an assistant professor at the University of Toronto, Dr. Blackman is actively involved in teaching and research.
MDRM believes that with the appointment of this highly qualified Advisory Board, it is establishing itself as a leader and innovator in the development of the Medical Cannabis industry in Canada.
About Modern Mobility Aids, Inc.
Modern Mobility Aids, Inc. is a public company in the biotechnology, life sciences and healthcare industry focused, in part, on the production, cultivation and selling of Medical Marijuana in North America. Our objective is to provide patients with access to a standardized and trusted supply of pharmaceutical grade cannabis developed and processed in accordance with rigorous health and safety standards and produced under Good Manufacturing Practices, the criteria used to manufacture all pharmaceuticals in the United States and Canada, ensuring a safe and reliable product. The Company is positioned to acquire interests in companies within the medical devices, biopharma and alternative medicine sectors targeting both innovative research and development as well as scalable licensed, manufacturing capacity in the three targeted niche market segments.
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding of discussion, the words “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. There are no guarantees or assurances that any proposals, initiatives or negotiations will result in what the company had originally intended. Any investment made into Modern Mobility Aids, Inc., would be classified as speculative and risky. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.